Cancer Family
Malignant Thoracic Neoplasm
CI-CAN-00000256Explore in graph →
2,773 active trials51 approved drugs626 evidence items
- NCIt
- C3576
Loading cancer entity…
Cancer Family
CI-CAN-00000256Explore in graph →
Clinical trials
11,496 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,526)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07761351 | A Randomized Controlled Trial Comparing Percutaneous CT-Guided Biopsy and Shape-Sensing Robotic-Assisted Bronchoscopy(ENCOMPASS) | recruiting | Phase 4 | 550 | Intuitive SurgicalINDUSTRY | 3 | Sep 25, 2026 | clinicaltrials |
| NCT03340506 | Dabrafenib and/or Trametinib Rollover Study | recruiting | Phase 4 | 100 | Novartis PharmaceuticalsINDUSTRY | 14 | Sep 23, 2026 | clinicaltrials |
| NCT05144997 | Lorlatinib Continuation Study | active not recruiting | Phase 4 | 76 | PfizerINDUSTRY | 8 | Sep 23, 2026 | clinicaltrials |
| NCT07822880 | A Study of Selpercatinib (LY3527723) in Participants With Rearranged During Transfection (RET)-Altered Cancers in India | not yet recruiting | Phase 4 | 30 | Eli Lilly and CompanyINDUSTRY | 1 | Sep 23, 2026 | clinicaltrials |
| NCT07633613 | Pharmacokinetic Study of Pembrolizumab and Its Impact on Immunity and the Tumor Microenvironment, Which May Explain the Efficacy of Post-immunotherapy Chemotherapy.(CPI) | not yet recruiting | Phase 4 | 110 | Centre Antoine LacassagneOTHER | 0 | Sep 15, 2026 | clinicaltrials |
| NCT07802847 | Innovative and Cooperative Pathway Integrating Oncogeriatric, Pharmaceutical and Pharmacological Follow-up in Elderly Patients.(POG) | not yet recruiting | Phase 4 | 794 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT07768358 | Tucatinib Continuation Study | not yet recruiting | Phase 4 | 175 | PfizerINDUSTRY | 0 | Aug 28, 2026 | clinicaltrials |
| NCT07279935 | Osimertinib Combined With Chemotherapy in Patients Who Had Distant Recurrence After Adjuvant Osimertinib for EGFRm Resectable SIB-IIIA NSCLC.(REVIVE) | recruiting | Phase 4 | 100 | AstraZenecaINDUSTRY | 1 | Aug 27, 2026 | clinicaltrials |
| NCT06908070 | Chemoradiotherapy With Surgery Followed by Consolidation Durvalumab(CROWD) | recruiting | Phase 4 | 38 | Idris BahceOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT07704658 | Pralsetinib DDI Study in Patients With Advanced or Metastatic Solid Tumors | recruiting | Phase 4 | 12 | Rigel PharmaceuticalsINDUSTRY | 1 | Aug 10, 2026 | clinicaltrials |
| NCT07754812 | Oral Paclitaxel Solution With Immunotherapy and Concurrent SBRT as Neoadjuvant Treatment for Older Adults With NSCLC | recruiting | Phase 4 | 78 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT07744698 | Metronomic Oral Paclitaxel Plus PD-1/ PD-L1 Inhibitor Maintenance in Advanced Lung Cancer (PULSE Study)(PULSE) | recruiting | Phase 4 | 107 | Anhui Provincial Cancer HospitalOTHER | 1 | Aug 4, 2026 | clinicaltrials |
| NCT07405086 | Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study | recruiting | Phase 4 | 160 | OHSU Knight Cancer InstituteOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT07567313 | Stage IV Lung Squamous Cell Carcinoma Treated With or Without Bronchial Artery Chemoembolization After First-line Chemotherapy and Immunotherapy | not yet recruiting | Phase 4 | 166 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 0 | May 5, 2026 | clinicaltrials |
| NCT06646471 | PROspective Master-protocol for Evaluation of Systemic THErapeutics in Elderly With Thoracic Malignancies(PROMETHEE) | recruiting | Phase 4 | 500 | GFPC InvestigationOTHER | 1 | Apr 29, 2026 | clinicaltrials |
| NCT06330038 | Anesthesia and Non-small Cell Lung Cancer Recurrence(GASTIVA) | recruiting | Phase 4 | 5,384 | Samsung Medical CenterOTHER | 1 | Apr 20, 2026 | clinicaltrials |
| NCT06282874 | Lorlatinib in Patients With ALK-Positive NSCLC With Brain or Leptomeningeal Metastases | active not recruiting | Phase 4 | 41 | Guangdong Association of Clinical TrialsOTHER | 1 | Apr 9, 2026 | clinicaltrials |
| NCT05160922 | Crizotinib Continuation Clinical Study | active not recruiting | Phase 4 | 27 | PfizerINDUSTRY | 5 | Mar 30, 2026 | clinicaltrials |
| NCT07485920 | A Prospective, Multicenter Exploratory Clinical Study on Consolidation Therapy With Tislelizumab Combined With Nintedanib for Limited-stage Small Cell Lung Cancer | not yet recruiting | Phase 4 | 20 | The Affiliated Hospital of Qingdao UniversityOTHER | 1 | Mar 20, 2026 | clinicaltrials |
| NCT07469488 | A Clinical Trial on the Outcomes of Comprehensive Enhanced Prophylaxis Management (CEPM) in Chinese Patients With EGFR-Mutated Advanced NSCLC Receiving Amivantamab-Based Regimens(AmiCARE) | not yet recruiting | Phase 4 | 122 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | Mar 13, 2026 | clinicaltrials |
| NCT05521789 | Erector Spinae Block for Thoracic Surgery | recruiting | Phase 4 | 70 | George Washington UniversityOTHER | 1 | Feb 25, 2026 | clinicaltrials |
| NCT06105801 | EBUS-TBNA vs Transbronchial Mediastinal Cryobiopsy for Adequacy of Next Generation Sequencing(FROSTBITE-3) | recruiting | Phase 4 | 250 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | Feb 2, 2026 | clinicaltrials |
| NCT07320105 | Postoperative Radiotherapy for Postoperative N2 Metastases of NSCLC in the Immunotherapy Era (Phase II) | recruiting | Phase 4 | 60 | Fujian Cancer HospitalOTHER_GOV | 1 | Jan 6, 2026 | clinicaltrials |
| NCT05874401 | Trilaciclib vs Placebo in Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC) Receiving Topotecan | recruiting | Phase 4 | 302 | Pharmacosmos A/SINDUSTRY | 1 | Sep 4, 2025 | clinicaltrials |
| NCT07092202 | Firmonertinib Combined With Intrathecal Injection for the Treatment of EGFR Mutant NSCLC With Leptomeningeal Metastases | recruiting | Phase 4 | 40 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Jul 29, 2025 | clinicaltrials |
| NCT06951841 | Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum and Immune Checkpoint Inhibitors Combined With Anlotinib for the Maintenance of Extensive Small Cell Lung Cancer After First-line Induction | not yet recruiting | Phase 4 | 31 | China Medical University, ChinaOTHER | 1 | Apr 30, 2025 | clinicaltrials |
| NCT06931145 | Benmelstobart, Anlotinib and Chemotherapy as First-line Treatment for Extensive-stage Small-cell Lung Cancer | not yet recruiting | Phase 4 | 50 | Peking Union Medical College HospitalOTHER | 1 | Apr 23, 2025 | clinicaltrials |
| NCT06893354 | Explore the Mechanisms Underlying Disease Resistance and Potential Primary Resistance Mechanism of Induction Therapy Lorlatinib in Resectable Non-small Cell Lung Cancer (NSCLC) Harboring ALK Positive Mutation Revealed by Single-cell RNA Sequencing and Spatial Transcriptomics | not yet recruiting | Phase 4 | 20 | The First Affiliated Hospital of Guangzhou Medical UniversityOTHER | 0 | Mar 25, 2025 | clinicaltrials |
| NCT05463913 | Lung Nodule Detection Using Ultra-long FOV PET/CT | recruiting | Phase 4 | 20 | University Medical Center GroningenOTHER | 1 | Mar 7, 2025 | clinicaltrials |
| NCT06785584 | Efficacy and Safety of Ensartinib in Neoadjuvant Therapy for Stage IIA - IIIB (Operable or Potentially Operable) ALK-Positive Lung Adenocarcinoma :A Multicenter, Real-World Clinical Study | not yet recruiting | Phase 4 | 30 | Fujian Medical University Union HospitalOTHER | 1 | Jan 21, 2025 | clinicaltrials |
| NCT06483009 | Efficacy and Safety of Combination Therapy of Sintilimab and Chemotherapy With Cryoablation in NSCLC | not yet recruiting | Phase 4 | 20 | Shanghai Chest HospitalOTHER | 0 | Aug 30, 2024 | clinicaltrials |
| NCT06467786 | Study on the Therapeutic Effect of Irinotecan Liposomes in Small Cell Lung Cancer | recruiting | Phase 4 | 24 | Tang-Du HospitalOTHER | 1 | Jun 21, 2024 | clinicaltrials |
| NCT05525338 | Comparison of Standard Dose Alectinib to Alectinib in Adjusted Dose Based on Alectinib Bloodlevels(ADAPT ALEC) | recruiting | Phase 4 | 196 | University Medical Center GroningenOTHER | 2 | May 13, 2024 | clinicaltrials |
| NCT06276933 | A Study of Camrelizumab Combined With Chemotherapy ± Thalidomide in First-line Treatment of Patients With Advanced Non-small Cell Lung Cancer (NSCLC) | not yet recruiting | Phase 4 | 104 | Tongji UniversityOTHER | 0 | Feb 26, 2024 | clinicaltrials |
| NCT05663242 | The Effects of Using Different Anesthetics on the Prognosis of Primary Lung Tumors and Its Mechanism of Action | recruiting | Phase 4 | 300 | Kaohsiung Medical University Chung-Ho Memorial HospitalOTHER | 1 | May 30, 2023 | clinicaltrials |
| NCT05518383 | B-cell Mature Non-Hodgkin's Lymphoma Treatment Protocol in Children and Adolescents 2021 | recruiting | Phase 4 | 300 | Federal Research Institute of Pediatric Hematology, Oncology and ImmunologyOTHER | 1 | Aug 26, 2022 | clinicaltrials |
| NCT05172739 | Opioid Free Anaesthesia-Analgesia Strategy on Surgical Stress and Immunomodulation in Elective VATS-Lobectomy for NSCLC | recruiting | Phase 4 | 70 | University of CreteOTHER | 1 | Dec 29, 2021 | clinicaltrials |
Data updated 4 days agoSource updated Sep 25, 2026source: clinicaltrials